# Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy

> **NCT01192087** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Heidelberg University** · enrollment: 49 (estimated)

## Conditions studied

- Adenoid Cystic Carcinoma

## Interventions

- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01192087
- **Lead sponsor:** Heidelberg University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-06
- **Primary completion:** 2015-07
- **Final completion:** 2017-07
- **Target enrollment:** 49 (ESTIMATED)
- **Last updated:** 2013-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01192087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01192087, "Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01192087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*